文献速递肝病消化道肿瘤与早癌

接受直接抗病毒药物治疗的丙型肝炎患者的肝细胞癌风险

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
PubMed 文献 · Gastroenterology · 2017-06-19

该回顾性队列研究纳入2015年在129家退伍军人健康管理医院接受直接抗病毒药物治疗的22500例丙型肝炎患者,分析持续病毒学应答与肝细胞癌风险的关系。持续病毒学应答者肝细胞癌风险显著降低(0.90 vs 3.45例/100人年;校正风险比0.28,95%CI 0.22-0.36),但肝硬化患者持续病毒学应答后肝细胞癌绝对风险仍高。

要点

  • 持续病毒学应答者肝细胞癌风险显著低于无应答者(校正风险比0.28,95%CI 0.22-0.36)。
  • 肝硬化患者持续病毒学应答后肝细胞癌年发病率最高(1.82 vs 无肝硬化0.34例/100人年;校正风险比4.73,95%CI 3.34-6.68)。
  • 持续病毒学应答后肝硬化患者肝细胞癌绝对风险仍高,应考虑持续肝细胞癌监测。

核心结论

  • 在直接抗病毒药物治疗的患者中,持续病毒学应答与肝细胞癌风险大幅降低相关。
  • 未发现任何证据提示直接抗病毒药物会促进肝细胞癌。
  • 在持续病毒学应答患者中,已确诊肝硬化者的肝细胞癌绝对风险仍高,这些患者应考虑持续肝细胞癌监测。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月1日至2015年12月31日在129家退伍军人健康管理医院接受直接抗病毒药物治疗的丙型肝炎病毒患者。
  • 共22500例接受直接抗病毒药物治疗的患者,其中19518例获得持续病毒学应答,2982例未获得持续病毒学应答。
  • 平均(标准差)年龄61.6(6.1)岁,39.0%有肝硬化。

主要发现

  • 共271例新发肝细胞癌,其中183例发生于持续病毒学应答患者。
  • 持续病毒学应答者与无持续病毒学应答者相比,肝细胞癌风险显著降低(0.90 vs 3.45例/100人年;校正风险比0.28,95%CI 0.22-0.36)。
  • 肝硬化患者持续病毒学应答后肝细胞癌年发病率最高(1.82 vs 无肝硬化患者0.34例/100人年;校正风险比4.73,95%CI 3.34-6.68)。
  • 多数(>44.8%)肝细胞癌分类为I期。
  • 超过75%的病例最大病灶最大径≤5 cm。

临床怎么用

  • 作者认为,持续病毒学应答后肝硬化患者肝细胞癌绝对风险仍高,这些患者应考虑持续肝细胞癌监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The risk of hepatocellular cancer (HCC) after sustained virological response (SVR) with direct-acting antivirals (DAA) is unclear. Our aim was to examine the risk and determinants of HCC in patients cured with DAA. METHODS: We conducted a retrospective cohort study of hepatitis C virus patients who were treated with DAA in any of the 129 Veterans Health Administration hospitals between January 1, 2015 and December 31, 2015. We calculated the annual incidence rates of HCC by SVR. We used Cox regression models to compare the risk of HCC in patients with vs those without SVR and to identify factors associated with incident HCC among patients with SVR. We reviewed a sample of HCC patients for tumor size and stage at diagnosis. RESULTS: Among 22,500 patients treated with DAA (19,518 with SVR; 2982 without SVR), the mean (standard deviation) age was 61.6 (6.1) years, and 39.0% had cirrhosis. There were 271 new cases of HCC, including 183 in patients with SVR. Compared with patients without SVR, those with SVR had a significantly reduced risk of HCC (0.90 vs 3.45 HCC/100 person-years; adjusted hazard ratio, 0.28, 95% CI=0.22-0.36). Patients with cirrhosis had the highest annual incidence of HCC after SVR (1.82 vs 0.34/100 person-years in patients without cirrhosis; adjusted hazard ratio, 4.73. 95% CI, 3.34-6.68). Most (>44.8%) HCC were classified as stage I. Maximum size of the largest lesion was ≤5 cm in over 75% of cases. CONCLUSIONS: Among patients treated with DAA, SVR was associated with a considerable reduction in the risk of HCC. We did not find any evidence to suggest that DAAs promote HCC. However, in patients with SVR, the absolute risk of HCC remained high in patients with established cirrhosis. These patients should be considered for ongoing HCC surveillance.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017. PMID: 28642197. doi:10.1053/j.gastro.2017.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。